Rumors of upped Amgen bid for Onyx

Amgen Inc. (NASDAQ:AMGN) and cancer company Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) declined to comment on media reports that Amgen raised its bid to acquire Onyx to $130 per share in cash, or about $9.5 billion. Last month, Onyx's board rejected an unsolicited offer from Amgen to acquire Onyx for $120 per share in cash, or about $8.7 billion. However, at the time the company said it was open to additional offers (see BioCentury Extra, July 1). ...